Does lovastatin inhibit HMG-CoA reductase?

Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol.

What type of inhibitor is lovastatin?

Lovastatin is a potent competitive inhibitor of the rate-limiting enzyme of cholesterol synthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (NADPH) [HMG-CoA reductase; (S)-mevalonate:NADP+ oxidoreductase (CoA-acylating), EC 1.1. 1.34].

What is the action of HMG-CoA reductase inhibitors?

Introduction. Also known as statins, HMG-CoA reductase inhibitors work by inhibiting the synthesis of cholesterol in the liver by the enzyme HMG-CoA reductase.

Which is the HMG CoA reductase inhibitor?

A substance that blocks an enzyme needed by the body to make cholesterol and lowers the amount of cholesterol in the blood. HMG-CoA reductase inhibitor drugs are called statins. Also called hydroxymethylglutaryl-coenzyme A reductase inhibitor.

Which is the best HMG CoA reductase inhibitor?

A drug used to lower the amount of cholesterol in the blood. It is also being studied in the prevention and treatment of some types of cancer. Lovastatin is a type of HMG-CoA reductase inhibitor (statin). A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent.

How does rosuvastatin inhibit HMG-CoA reductase?

Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol.

How does Crestor work on HMG-CoA reductase?

Crestor blocks an enzyme that helps make cholesterol in the body and it helps break down cholesterol. It also may cause cancer cells to die and may inhibit the growth of blood vessels that cancer cells need to grow. It is a type of HMG-CoA reductase inhibitor and a type of statin.

Which is better lovastatin or HMGCR in mice?

Mice were gavaged with vehicle or lovastatin for 7 consecutive days and hepatic HMGCR protein was examined using immunoblotting. The amounts of HMGCR protein in mice receiving lovastatin were 58-fold higher than that from vehicle-treated mice (Fig. 1a, b ).